Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (6)
  • Penn Non-Treatment Trials (8)
  • Phase 1: Solid Tumor Trials (3)
  • Proton Therapy Trials (1)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
NCI-2009-00587 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer III Chemotherapy, Signal Transduction Inhibitor docetaxel; carboplatin; bevacizumab; paclitaxel
UPCC 03909 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer II Signal Transduction Inhibitor PD 0332991
GOG-0186G A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer II Signal Transduction Inhibitor bevacizumab; everolimus
ATI0918-101 A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy I Chemotherapy pegylated-liposomal doxorubicin (PLD); ATI-0918
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy BMS-663513
UPCC 19809 A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer 0 Immunotherapy OC-DC Vaccine
Displaying: 1 - 6 of 6 Results
  • < Previous
  • 1
  • Next >